期刊文献+

血清前白蛋白总胆红素比值在肝脏TACE术患者预后评估中的应用价值 被引量:4

Application value of serum total bilirubin ratio of prealbumin in prognosis evaluation of patients undergoing liver TACE
下载PDF
导出
摘要 目的探讨前白蛋白总胆红素比值评估经肝动脉化疗栓塞术(TACE)预后的价值。方法回顾性分析我院2012年5月~2017年5月133例行TACE术的原发性肝癌患者的详细资料,把术前、术后3d的前白蛋白与总胆红素比值作为研究指标。应用ROC曲线计算预测2年生存的最佳截断值,生存率采用Kaplan-Meier法,使用Cox行多因素分析。结果患者均行介入治疗,前白蛋白总胆红素比值术前中位数为6.85,术后3d中位数为3.92,表现为明显下降;ROC曲线显示术前﹑术后3d预测2年生存的最佳截断值为6.877、3.955,其中术后前白蛋白总胆红素比值对患者预后有更好的诊断价值;术前和术后的高低两组生存率差异有统计学意义(χ~2=24.966、53.969,P<0.05);肿瘤直径、肿瘤数目、白蛋白及前白蛋白总胆红素比值是影响总体生存时间的独立危险因素。结论前白蛋白总胆红素比值可作为评估患者预后的实用指标。 Objective To explore the value of serum total bilirubin ratio of prealbumin in evaluating the prognosis of patients undergoing TACE.Methods The detailed data of 133 patients with primary liver cancer who underwent TACE from May 2012 to May 2017 in our hospital were analyzed.The total bilirubin ratio of prealbumin before and after TACE were collected as the research index.The optimal cutoff value of 2-year survival was calculated by ROC curve,and the survival rate was calculated by Kaplan-Meier curve.Results All patients were treated with interventional therapy.The preoperative median value of the serum total bilirubin ratio of prealbumin was 6.85,and the postoperative median value was 3.92.The ROC curve showed that the best cut-off point for predicting 2-year survival was 6.877 and 3.955,among which the preoperative and postoperative median value of total bilirubin was better for the prognosis of patients value.The difference of survival rate between the high and low groups was statistically significant before and after operation(χ2=24.966,53.969,P<0.05).Tumor diameter,tumor number,albumin and the total bilirubin ratio of prealbumin were the independent risk factors affecting the overall survival time of patients.Conclusion Total bilirubin ratio of prealbumin can be used as a practical index to evaluate the prognosis of patients.
作者 程序 周英发 贾萌萌 刘芳 马艳萍 黄琳凯 丁小丹 Cheng Xu;Zhou Yingfa;Jia Mengmeng(Department of Gastroenterology,the Second Affiliated Hospital of Zhengzhou University,Zhengzhou 450000)
出处 《中国现代医药杂志》 2020年第5期10-14,共5页 Modern Medicine Journal of China
关键词 肝细胞癌 化疗栓塞 前白蛋白总胆红素比值 预测 生存时间 Hepatocellular carcinoma Chemoembolization Total bilirubin ratio of prealbumin Forecasting Survival time
  • 相关文献

参考文献2

二级参考文献50

  • 1XinLi Gan-ShengFeng Chuan-ShengZheng Chen-KaiZhuo XiLiu.Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level[J].World Journal of Gastroenterology,2004,10(19):2878-2882. 被引量:54
  • 2韩克起,顾伟,苏永华,黄雪强,王喜,凌昌全.蟾毒灵抗小鼠原位移植性肝癌整体药效学研究[J].中华实验外科杂志,2004,21(12):1436-1438. 被引量:12
  • 3Jemal A,Bray F,Center MM,Ferlay J Ward E Forman D. Global cancer statistics[J].CA:A Cancer Journal for Clinicians,2011,(02):69-90.
  • 4Ferlay J,shin HR,Bray F,Forman D,Mathers C,Parkin DM. GLOBOCAN 2008:Cancer incidence and mortality worldwide:IARC CancerBase No.10[OL].http://www.iarc.fr/en/media-centre/iarcnews/2010/globocan2008.php,2011.
  • 5Ercolani G,Grazi GL,Ravaioli M,Del Gaudio M Gardini A Cescon M Varotti G Cetta F Cavallari A. Liver resection for hepatocellular carcinoma on cirrhosis:univariate and multivariate analysis of risk factors for intrahepatic recurrence[J].Annals of Surgery,2003,(04):536-543.
  • 6Bruix J,Sherman M,Practice Guidelines Committee,American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma[J].Hepatology,2005,(05):1208-1236.doi:10.1002/hep.20933.
  • 7Imamura H,Matsuyama Y,Tanaka E,Ohkubo T Hasegawa K Miyagawa S Sugawara Y Minagawa M Takayama T Kawasaki S Makuuchi M. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy[J].Journal of Hepatology,2003,(02):200-207.
  • 8Poon RT,Fan ST,Lo CM,Liu CL Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function:implications for a strategy of salvage transplantation[J].Annals of Surgery,2002,(03):373-382.
  • 9Llovet JM,Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma:Chemoembolization improves survival[J].Hepatology,2003,(02):429-442.doi:10.1053/jhep.2003.50047.
  • 10Takayama T,Sekine T,Makuuchi M,Yamasaki S Kosuge T Yamamoto J Shimada K Sakamoto M Hirohashi S Ohashi Y Kakizoe T. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma:a randomised trial[J].The Lancet,2000,(9232):802-807.

共引文献106

同被引文献40

引证文献4

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部